Associated Papers
Assessing endocrine resistance: monitoring circulating ESR1 mutations in Irosustat-treated ER positive breast cancer.
Page K et al.
Breast Cancer Research and Treatment, 2025
41364261 (PubMed )
Supplement: 10549_2025_7857_MOESM7_ESM.xlsx › Supp_Table_2
Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy in endocrine therapy-resistant breast cancer.
Wang M et al.
Neoplasia (new York, N.y.), 2025
ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
Herzog SK et al.
British Journal of Cancer, 2022
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.
Pejerrey SM et al.
Hormones & Cancer, 2018
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z et al.
International Journal of Molecular Sciences, 2016
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?
Tabarestani S et al.
Iranian Journal of Cancer Prevention, 2016
Mutations and polymorphisms of estrogens receptors genes and diseases susceptibility.
Kallel I et al.
Journal of Receptor and Signal Transduction Research, 2012
Estrogen receptor variants.
Hopp TA et al.
Journal of Mammary Gland Biology and Neoplasia, 1998
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.
Zhang QX et al.
Cancer Research, 1997
[ESR1 gene allelic polymorphism analysis in population of Ukraine].
Livshyts' GB et al.
Tsitologiia I Genetika, 0
[A population genetics study of the allelic polymorphism in the hypervariable region of the apolipoprotein B gene in the population of different regions of Ukraine].
Kravchenko SA et al.
Tsitologiia I Genetika, 0
Select a paper to view details